Annual Drug Patent Expirations for OTEZLA
Otezla is a drug marketed by Amgen Inc and is included in one NDA. It is available from three suppliers. There are eleven patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for OTEZLA.
This drug has seventy-four patent family members in twenty-four countries.
The generic ingredient in OTEZLA is apremilast. Three suppliers are listed for this compound. Additional details are available on the apremilast profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com